Citations 3
Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.
Crump, Michael , Neelapu, Sattva S. , Neste, Éric Van Den, Ahmed, Mohamed , Zhu, Liting , Feng, Lei, Navale, Lynn, Wiezorek, Jeffrey S., Go, William Y., Gisselbrecht, Christian , Farooq, Umar , Kuruvilla, John , Link, Brian K. , Hay, Annette E. , Cerhan, James R. , Boussetta, Sami , Maurer, Matthew J.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7516-7516
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
Bachy, Emmanuel , Habermann, Thomas M., Gelas‐Dore, Bénédicte, Estell, Jane, Neste, Éric Van Den, Bouabdallah, Réda, Gyan, Emmanuel , Bargay, Joan , Slager, Susan L., Silva, María Gomes da , Fitoussi, Olivier , Intragumtornchai, Tanin , Ansell, Stephen M., Lamy, T. , Dartigues, Peggy , Link, Brian K. , Seymour, John F., Salles, Gilles , Link, Brian K , Gyan, Emmanuel , Salles, Gilles A , Maurer, Matthew J. , Habermann, Thomas M. , Maucort‐Boulch, Delphine , Feldman, Andrew L. , Delmer, Alain , Slager, Susan L. , Belada, David , Maisonneuve, Hervé , Ansell, Stephen M. , Cerhan, James R. , Bachy, Emmanuel
Blood | April 17, 2018 | Volume: 132 | Issue: 1 | Pages: 49-58
Key Points In FL, no prognostic index has been built based solely on a large cohort of patients treated with initial immunochemotherapy. The PRIMA-PI is a simplified index based on β2m and bone marrow involvement for patients treated with immunochemotherapy.
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, Michael , Neelapu, Sattva S. , Farooq, Umar , Neste, Éric Van Den, Westin, Jason R. , Link, Brian K. , Hay, Annette E. , Zhu, Liting , Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian , Link, Brian K , Farooq, Umar , Westin, Jason R , Kuruvilla, John , Cerhan, James R. , Boussetta, Sami , Feng, Lei , Maurer, Matthew J.
Blood | August 3, 2017 | Volume: 130 | Issue: 16 | Pages: 1800-1808
Key Points SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.